Jakavi / Jakafi (Ruxolitinib) (Ruxolitinib) — Uses, Dosage, Side Effects & Safety

Drug class: Autoimmune & Immunological

Overview

Jakavi / Jakafi (Ruxolitinib) is a prescription medication used to treat certain blood disorders, including myelofibrosis (a type of bone marrow cancer), polycythemia vera (a condition with too many red blood cells), and steroid-refractory acute graft-versus-host disease (GVHD) in adults and children over 12 years old. It works by blocking specific enzymes called Janus kinases (JAK1 and JAK2), which play a role in the production of blood cells and immune system activity. By inhibiting these enzymes, Ruxolitinib helps reduce symptoms like enlarged spleen, night sweats, itching, and fatigue. Key points for patients: Take this medication exactly as prescribed, do not stop suddenly without consulting your doctor, and report any signs of infection, unusual bruising, or bleeding. Regular blood tests are necessary to monitor your response and safety.

Therapeutic uses

  • Myelofibrosis
  • Polycythemia Vera
  • Acute Graft-versus-Host Disease (aGVHD)
  • Chronic Graft-versus-Host Disease (cGVHD)

Common side effects

  • Thrombocytopenia
  • Anemia
  • Neutropenia
  • Bruising
  • Dizziness
  • Headache
  • Diarrhea
  • Increased liver enzymes

Frequently Asked Questions about Jakavi / Jakafi (Ruxolitinib)

What is Jakafi?

Oral JAK1/JAK2 inhibitor; generic name ruxolitinib.

What is ruxolitinib used for?

Intermediate/high-risk myelofibrosis, polycythemia vera (hydroxyurea-intolerant/resistant), steroid-refractory acute & chronic GVHD.

Is Jakafi chemotherapy?

No — targeted JAK inhibitor, not traditional chemotherapy.

What are the side effects of Jakafi?

Anemia, thrombocytopenia, neutropenia, bruising, dizziness, headache, infections, herpes zoster reactivation.

Does Jakafi cause anemia?

Yes — common (dose-dependent); usually improves over time.

How long can you stay on Jakafi?

Long-term/indefinite in responding patients (many >5–10 years).

Is there a generic for Jakafi?

No FDA-approved generic as of November 2025.

What is the starting dose of Jakafi for myelofibrosis?

15–20 mg twice daily based on platelet count.

Related Jakavi / Jakafi (Ruxolitinib) information

Educational information only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.